Product logins

Find logins to all Clarivate products below.


Type 2 Diabetes (Fixed-Dose Combinations) | Decision Base | US/EU | 2014

Are Emerging Fixed-Dose Combinations Poised to Fill the Unmet Need for Drugs with Greater Efficacy?

Type 2 diabetes is a major public health concern, affecting more than 30 million people in the United States alone. A newly diagnosed type 2 diabetic is usually prescribed metformin and lifestyle modification, but as the disease progresses, these patients will be prescribed either additional oral antidiabetic agents or insulin therapy. Because type 2 diabetes patients often take multiple pills for their condition as well as other comorbidities, physicians see fixed-dose combinations (FDCs) as a way to improve convenience and patients’ compliance if they already have a high pill burden. In this report we compare current FDCs used to treat type 2 diabetes and explore which FDCs in development will help to meet the unmet needs identified by physicians and payers.

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…